Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Spinal Muscular Atrophy Market, by Type
1.4.2 Global Spinal Muscular Atrophy Market, by Route of Administration
1.4.3 Global Spinal Muscular Atrophy Market, by Treatment Type
1.4.4 Global Spinal Muscular Atrophy Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market
Chapter 4. Global Spinal Muscular Atrophy Treatment Market by Type
4.1 Global Type 1 Market by Region
4.2 Global Type 2 Market by Region
4.3 Global Type 3 Market by Region
4.4 Global Type 4 Market by Region
Chapter 5. Global Spinal Muscular Atrophy Treatment Market by Route of Administration
5.1 Global Injection Market by Region
5.2 Global Oral Market by Region
Chapter 6. Global Spinal Muscular Atrophy Treatment Market by Treatment Type
6.1 Global Drug Market by Region
6.2 Global Spinal Muscular Atrophy Treatment Market by Drug Type
6.2.1 Global Spinraza Market by Region
6.2.2 Global Zolgensma (AVXS-101) Market by Region
6.2.3 Global Evrysdi Market by Region
6.2.4 Global Others Market by Region
6.3 Global Gene Therapy Market by Region
Chapter 7. Global Spinal Muscular Atrophy Treatment Market by Region
7.1 North America Spinal Muscular Atrophy Treatment Market
7.1.1 North America Spinal Muscular Atrophy Treatment Market by Type
7.1.1.1 North America Type 1 Market by Country
7.1.1.2 North America Type 2 Market by Country
7.1.1.3 North America Type 3 Market by Country
7.1.1.4 North America Type 4 Market by Country
7.1.2 North America Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.2.1 North America Injection Market by Country
7.1.2.2 North America Oral Market by Country
7.1.3 North America Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.3.1 North America Drug Market by Country
7.1.3.2 North America Spinal Muscular Atrophy Treatment Market by Drug Type
7.1.3.2.1 North America Spinraza Market by Country
7.1.3.2.2 North America Zolgensma (AVXS-101) Market by Country
7.1.3.2.3 North America Evrysdi Market by Country
7.1.3.2.4 North America Others Market by Country
7.1.3.3 North America Gene Therapy Market by Country
7.1.4 North America Spinal Muscular Atrophy Treatment Market by Country
7.1.4.1 US Spinal Muscular Atrophy Treatment Market
7.1.4.1.1 US Spinal Muscular Atrophy Treatment Market by Type
7.1.4.1.2 US Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.4.1.3 US Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.4.1.3.1 US Spinal Muscular Atrophy Treatment Market by Drug Type
7.1.4.2 Canada Spinal Muscular Atrophy Treatment Market
7.1.4.2.1 Canada Spinal Muscular Atrophy Treatment Market by Type
7.1.4.2.2 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.4.2.3 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.4.2.3.1 Canada Spinal Muscular Atrophy Treatment Market by Drug Type
7.1.4.3 Mexico Spinal Muscular Atrophy Treatment Market
7.1.4.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Type
7.1.4.3.2 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.4.3.3 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.4.3.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type
7.1.4.4 Rest of North America Spinal Muscular Atrophy Treatment Market
7.1.4.4.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Type
7.1.4.4.2 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.4.4.3 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.4.4.3.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type
7.2 Europe Spinal Muscular Atrophy Treatment Market
7.2.1 Europe Spinal Muscular Atrophy Treatment Market by Type
7.2.1.1 Europe Type 1 Market by Country
7.2.1.2 Europe Type 2 Market by Country
7.2.1.3 Europe Type 3 Market by Country
7.2.1.4 Europe Type 4 Market by Country
7.2.2 Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.2.1 Europe Injection Market by Country
7.2.2.2 Europe Oral Market by Country
7.2.3 Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.3.1 Europe Drug Market by Country
7.2.3.2 Europe Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.3.2.1 Europe Spinraza Market by Country
7.2.3.2.2 Europe Zolgensma (AVXS-101) Market by Country
7.2.3.2.3 Europe Evrysdi Market by Country
7.2.3.2.4 Europe Others Market by Country
7.2.3.3 Europe Gene Therapy Market by Country
7.2.4 Europe Spinal Muscular Atrophy Treatment Market by Country
7.2.4.1 Germany Spinal Muscular Atrophy Treatment Market
7.2.4.1.1 Germany Spinal Muscular Atrophy Treatment Market by Type
7.2.4.1.2 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.1.3 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.1.3.1 Germany Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.4.2 UK Spinal Muscular Atrophy Treatment Market
7.2.4.2.1 UK Spinal Muscular Atrophy Treatment Market by Type
7.2.4.2.2 UK Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.2.3 UK Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.2.3.1 UK Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.4.3 France Spinal Muscular Atrophy Treatment Market
7.2.4.3.1 France Spinal Muscular Atrophy Treatment Market by Type
7.2.4.3.2 France Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.3.3 France Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.3.3.1 France Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.4.4 Russia Spinal Muscular Atrophy Treatment Market
7.2.4.4.1 Russia Spinal Muscular Atrophy Treatment Market by Type
7.2.4.4.2 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.4.3 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.4.3.1 Russia Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.4.5 Spain Spinal Muscular Atrophy Treatment Market
7.2.4.5.1 Spain Spinal Muscular Atrophy Treatment Market by Type
7.2.4.5.2 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.5.3 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.5.3.1 Spain Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.4.6 Italy Spinal Muscular Atrophy Treatment Market
7.2.4.6.1 Italy Spinal Muscular Atrophy Treatment Market by Type
7.2.4.6.2 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.6.3 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.6.3.1 Italy Spinal Muscular Atrophy Treatment Market by Drug Type
7.2.4.7 Rest of Europe Spinal Muscular Atrophy Treatment Market
7.2.4.7.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type
7.2.4.7.2 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.4.7.3 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.4.7.3.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type
7.3 Asia Pacific Spinal Muscular Atrophy Treatment Market
7.3.1 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
7.3.1.1 Asia Pacific Type 1 Market by Country
7.3.1.2 Asia Pacific Type 2 Market by Country
7.3.1.3 Asia Pacific Type 3 Market by Country
7.3.1.4 Asia Pacific Type 4 Market by Country
7.3.2 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.2.1 Asia Pacific Injection Market by Country
7.3.2.2 Asia Pacific Oral Market by Country
7.3.3 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.3.1 Asia Pacific Drug Market by Country
7.3.3.2 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.3.2.1 Asia Pacific Spinraza Market by Country
7.3.3.2.2 Asia Pacific Zolgensma (AVXS-101) Market by Country
7.3.3.2.3 Asia Pacific Evrysdi Market by Country
7.3.3.2.4 Asia Pacific Others Market by Country
7.3.3.3 Asia Pacific Gene Therapy Market by Country
7.3.4 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country
7.3.4.1 China Spinal Muscular Atrophy Treatment Market
7.3.4.1.1 China Spinal Muscular Atrophy Treatment Market by Type
7.3.4.1.2 China Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.1.3 China Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.1.3.1 China Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.4.2 Japan Spinal Muscular Atrophy Treatment Market
7.3.4.2.1 Japan Spinal Muscular Atrophy Treatment Market by Type
7.3.4.2.2 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.2.3 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.2.3.1 Japan Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.4.3 India Spinal Muscular Atrophy Treatment Market
7.3.4.3.1 India Spinal Muscular Atrophy Treatment Market by Type
7.3.4.3.2 India Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.3.3 India Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.3.3.1 India Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.4.4 South Korea Spinal Muscular Atrophy Treatment Market
7.3.4.4.1 South Korea Spinal Muscular Atrophy Treatment Market by Type
7.3.4.4.2 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.4.3 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.4.3.1 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.4.5 Australia Spinal Muscular Atrophy Treatment Market
7.3.4.5.1 Australia Spinal Muscular Atrophy Treatment Market by Type
7.3.4.5.2 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.5.3 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.5.3.1 Australia Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.4.6 Malaysia Spinal Muscular Atrophy Treatment Market
7.3.4.6.1 Malaysia Spinal Muscular Atrophy Treatment Market by Type
7.3.4.6.2 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.6.3 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.6.3.1 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type
7.3.4.7 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
7.3.4.7.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
7.3.4.7.2 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.4.7.3 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.4.7.3.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type
7.4 LAMEA Spinal Muscular Atrophy Treatment Market
7.4.1 LAMEA Spinal Muscular Atrophy Treatment Market by Type
7.4.1.1 LAMEA Type 1 Market by Country
7.4.1.2 LAMEA Type 2 Market by Country
7.4.1.3 LAMEA Type 3 Market by Country
7.4.1.4 LAMEA Type 4 Market by Country
7.4.2 LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.2.1 LAMEA Injection Market by Country
7.4.2.2 LAMEA Oral Market by Country
7.4.3 LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.3.1 LAMEA Drug Market by Country
7.4.3.2 LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.3.2.1 LAMEA Spinraza Market by Country
7.4.3.2.2 LAMEA Zolgensma (AVXS-101) Market by Country
7.4.3.2.3 LAMEA Evrysdi Market by Country
7.4.3.2.4 LAMEA Others Market by Country
7.4.3.3 LAMEA Gene Therapy Market by Country
7.4.4 LAMEA Spinal Muscular Atrophy Treatment Market by Country
7.4.4.1 Brazil Spinal Muscular Atrophy Treatment Market
7.4.4.1.1 Brazil Spinal Muscular Atrophy Treatment Market by Type
7.4.4.1.2 Brazil Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.1.3 Brazil Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.1.3.1 Brazil Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.4.2 Argentina Spinal Muscular Atrophy Treatment Market
7.4.4.2.1 Argentina Spinal Muscular Atrophy Treatment Market by Type
7.4.4.2.2 Argentina Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.2.3 Argentina Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.2.3.1 Argentina Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.4.3 UAE Spinal Muscular Atrophy Treatment Market
7.4.4.3.1 UAE Spinal Muscular Atrophy Treatment Market by Type
7.4.4.3.2 UAE Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.3.3 UAE Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.3.3.1 UAE Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.4.4 Saudi Arabia Spinal Muscular Atrophy Treatment Market
7.4.4.4.1 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Type
7.4.4.4.2 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.4.3 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.4.3.1 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.4.5 South Africa Spinal Muscular Atrophy Treatment Market
7.4.4.5.1 South Africa Spinal Muscular Atrophy Treatment Market by Type
7.4.4.5.2 South Africa Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.5.3 South Africa Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.5.3.1 South Africa Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.4.6 Nigeria Spinal Muscular Atrophy Treatment Market
7.4.4.6.1 Nigeria Spinal Muscular Atrophy Treatment Market by Type
7.4.4.6.2 Nigeria Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.6.3 Nigeria Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.6.3.1 Nigeria Spinal Muscular Atrophy Treatment Market by Drug Type
7.4.4.7 Rest of LAMEA Spinal Muscular Atrophy Treatment Market
7.4.4.7.1 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Type
7.4.4.7.2 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.4.7.3 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.4.7.3.1 Rest of LAMEA Spinal Muscular Atrophy Treatment Market by Drug Type
Chapter 8. Company Profiles
8.1 PTC Therapeutics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.5.3 Approvals and Trials:
8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trials:
8.2.5.2 Acquisition and Mergers:
8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.4.5.2 Acquisition and Mergers:
8.5 Ionis Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Cytokinetics, Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expenses
8.8 Astellas Pharma, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 Biogen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. NMD Pharma A/S
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Geographical Expansions:
Unique Offerings 